Singapore-based cell therapy developer CytoMed Therapeutics Ltd (NASDAQ: GDTC) has announced the signing of a memorandum of understanding (MoU) with China’s Hangzhou CNK Therapeutics Co., Ltd. The agreement grants CytoMed a license to utilize CNK’s PiggyBac technology, enabling the permanent grafting of the Chimeric Antigen Receptor (CAR) gene into its gamma delta (γδ) T cells through a non-viral gene editing method.
Enhancing CAR T-Cell Therapy with CNK’s Technology
CytoMed’s primary focus lies in the development of “off-the-shelf” immunotherapeutics based on gamma delta (γδ) T cells and natural killer (NK) cells for a broad spectrum of cancers. Currently, the company employs mRNA technology for CAR gene therapy, which targets specific cancer cells temporarily. This transient function eventually ceases, leaving un-targeted γδ T cells in the patient’s body. The integration of CNK’s PiggyBac technology is anticipated to extend the duration for which those γδ T cells remain targeted towards cancer cells, potentially enhancing the efficacy of the treatment.
MoU Details and Future Collaborations
The MoU between CytoMed and CNK Therapeutics is valid for a period of one year, with an option to renew, pending the execution of a definitive agreement. The two companies are also reportedly contemplating a joint venture to conduct clinical trials in China, which would further solidify their partnership and expand the reach of their immunotherapeutic offerings.-Fineline Info & Tech
